Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch

Key cohort characteristics reported by the trial were similar in trial participants compared with possibly eligible real-world patients, although the median Charlson comorbidity index was lower in the trial cohort (table). No laboratory or physiological data from the time of the index blood culture was reported but might have been helpful to quantify disease severity and guide patient selection (appendix). Supplementary Material Supplementary appendix SABATO cohort (n=108) Real-world cohort (n=71) Age (years) 64·4 (SD 16·8) 63·2 (SD 17·6) Sex Male 71 (66%) 41 (57·7%) Female 37 (34%) 30 (42·3%) BMI (kg per m2) 27·6 (6·7) 28·3 (6·9), 3 missing data points Co-morbidities Moderate or severe liver disease 11 (10%) 8 (11·3%) Chronic renal failure 17 (16%) 7 (9·9%) End-stage renal failure 9 (8%) 4 (5·6%) Diabetes with end-organ damage 19 (18%) 13 (18·3%) Charlson comorbidity index 3 (IQR 1–5) 5 (IQR 2–7) Source of bacteraemia* Intravenous catheter 71 (66%) 31 (43·7%) Skin and soft-tissue infection 26 (24%) 17 (23·9%) Other† 5 (5%) 7 (9·9%) Unknown 6 (6%) 16 (22·5%) Resistance‡ Meticillin 6 (6%) 4 (5·6%) Clindamycin 12 (12%) 14 (19·7%) Co-trimoxazole 1 (1%) 4 (5·6%) Outcomes Attributable mortality 2 (2%) 4 (5·6%) 90-day survival rate 83·6% 84·5% Relapsing Staphylococcus aureus bacteraemia 3 (3%) 2 (2·8%) Table Comparison of cohort characteristics